Your browser doesn't support javascript.
loading
Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character).
Vatn, S; Carstens, A; Kristoffersen, A B; Bergemalm, D; Casén, C; Moen, A E F; Tannaes, T M; Lindstrøm, J; Detlie, T E; Olbjørn, C; Lindquist, C M; Söderholm, J D; Gomollón, F; Kalla, R; Satsangi, J; Vatn, M H; Jahnsen, J; Halfvarson, J; Ricanek, P.
Affiliation
  • Vatn S; Department of Gastroenterology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Carstens A; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Kristoffersen AB; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Bergemalm D; Department of Internal Medicine, Ersta Hospital, Stockholm, Sweden.
  • Casén C; Genetic Analysis AS, Oslo, Norway.
  • Moen AEF; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Tannaes TM; Genetic Analysis AS, Oslo, Norway.
  • Lindstrøm J; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Detlie TE; Department of Clinical Molecular Biology (EpiGen), Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Olbjørn C; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Lindquist CM; Department of Clinical Molecular Biology (EpiGen), Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Söderholm JD; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Gomollón F; Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway.
  • Kalla R; Department of Pediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Satsangi J; Department of Gastroenterology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Vatn MH; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Jahnsen J; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Halfvarson J; Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
  • Ricanek P; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Scand J Gastroenterol ; 55(10): 1146-1156, 2020 Oct.
Article in En | MEDLINE | ID: mdl-32780604
ABSTRACT

METHOD:

We examined faecal samples, using the GA-map™ Dysbiosis Test, to associate gut microbiota composition with Crohn's disease (CD) and ulcerative colitis (UC) and to identify markers for future biomarker identification. We conducted a prospective case-control study (EU-ref. no. 305676) in an inception cohort of 324 individuals (64 CD, 84 UC, 116 symptomatic non-IBD controls and 44 healthy controls) across five European centres and examined 54 predetermined bacterial markers. We categorized patients according to the Montreal Classification and calculated the dysbiosis index (DI). Non-parametric tests were used to compare groups and the Bonferroni correction to adjust for multiple comparisons.

RESULTS:

The fluorescent signals (FSSs) for Firmicutes and Eubacterium hallii were lower in inflammatory bowel disease (IBD) vs. symptomatic controls (p<.05). FSS for Firmicutes, Lachnospiraceae, Eubacterium hallii and Ruminococcus albus/bromii were lower, whereas the signal for Bacteroides Fragilis was higher in UC vs. symptomatic controls (p<.05). FSS was higher for Bifidobacterium spp., Eubacterium hallii, Actinobacteria and Firmicutes among patients with ulcerative proctitis, compared to extensive colitis (p<.05). In CD, we observed no association with disease location. The DI correlated with faecal-calprotectin in both CD and in UC (p<.001). In terms of treatment escalation and anti-TNF response, differences were observed for some bacterial markers, but none of these associations were statistically significant.

CONCLUSION:

Our data reveal that the GA-map™ Dysbiosis Test holds the potential to characterize the faecal microbiota composition and to assess the degree of dysbiosis in new-onset IBD. On the other hand, our results cannot demonstrate any proven diagnostic or predictive value of this method to support clinical decision making.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Colitis, Ulcerative / Gastrointestinal Microbiome Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Scand J Gastroenterol Year: 2020 Document type: Article Affiliation country: Norway

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Colitis, Ulcerative / Gastrointestinal Microbiome Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Scand J Gastroenterol Year: 2020 Document type: Article Affiliation country: Norway
...